ACT	Adoptive cellular therapy
APC	Antigen presenting cell
CAR	Chimeric antigen receptor
CDK	Cyclin-dependent kinase
CI	Confidence interval
CML	Chronic myeloid leukemia
CRISPR	Clustered regularly interspaced short palindromic repeats
CTL	Cytotoxic T-lymphocyte
CTLA-4	Cytotoxic T-lymphocyte-associated protein 4
DC	Dendritic cell
DNA	Deoxyribonucleic acid
FasL	Fas ligand
HLA	Human leukocyte antigen
ICI	Immune checkpoint inhibitor
IFN	Interferon
Ig	Immunoglobulin
IL	Interleukin
ITIM	Immunoreceptor tyrosine-based inhibition motif
LAG-3	Lymphocyte activation gene 3 protein
LFT	Liver function test
mAbs	Monoclonal antibodies
MHC	Major histocompatibility complex
NF-kB	Nuclear factor kB
NHL	Non-Hodgkin’s lymphoma
NK	Natural killer
NSCLC	Non-small cell lung cancer
OS	Overall survival
pCR	Pathologic complete response rates
PD-1	Programmed cell death protein 1
PD-L1	Programmed death-ligand 1
PFS	Progression free survival
RCC	Renal cell carcinoma
TCR	T cell receptor
TGF	Transforming growth factor
TIL	Tumor infiltrating lymphocyte
TIM-3	T cell Ig mucin domain-containing 3
TME	Tumor microenvironment
TNBC	Triple negative breast cancer
TNF	Tumor necrosis factor
TNFR	Tumor necrosis factor receptor
TNFRSF4	Tumor necrosis factor receptor superfamily member 4
TRAEs	Treatment-related adverse effects
Treg	Regulatory T cell
VEGF	Vascular endothelial growth factor
VEGFR	Vascular endothelial growth factor receptor
VISTA	V-domain Ig suppressor of t-cell activation